|
RAB38 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.34080000000025E-05 |
| Normal-vs-Stage3 |
2.89768209427166E-14 |
| Normal-vs-Stage4 |
2.73919997795247E-10 |
| Stage1-vs-Stage2 |
3.074400E-01 |
| Stage1-vs-Stage3 |
1.773040E-01 |
| Stage1-vs-Stage4 |
1.875240E-01 |
| Stage2-vs-Stage3 |
7.330400E-01 |
| Stage2-vs-Stage4 |
8.681400E-01 |
| Stage3-vs-Stage4 |
8.085200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.62682000000025E-05 |
| Normal-vs-Asian |
1.3655000463686E-09 |
| Caucasian-vs-AfricanAmerican |
4.013400E-01 |
| Caucasian-vs-Asian |
7.074600E-01 |
| AfricanAmerican-vs-Asian |
5.364400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.45137243837235E-13 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
4.002600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.23074900165921E-14 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.96653804351854E-12 |
| Normal-vs-Age(81-100Yrs) |
2.869900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.056200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.092780E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.310200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.993600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.787600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.859400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.144500E-03 |
| Classical-VS-Follicular |
1.190240E-01 |
| Classical-VS-Other |
6.961600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.656770E-01 |
| Tall-VS-Other |
2.901200E-01 |
| Tall-VS-Normal |
3.16950021783668E-10 |
| Follicular-VS-Other |
8.538600E-01 |
| Follicular-VS-Normal |
2.07549533115525E-11 |
| Other-VS-Normal |
5.899900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62470037423645E-12 |
| Normal-vs-N1 |
1.18140000004985E-07 |
| N0-vs-N1 |
3.083600E-01 |
|
|
